|Bid||24.44 x 1000|
|Ask||90.00 x 800|
|Day's Range||78.26 - 80.35|
|52 Week Range||44.52 - 127.77|
|Beta (3Y Monthly)||0.65|
|PE Ratio (TTM)||19.98|
|Earnings Date||Nov 26, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||104.00|
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return Read More...
HENDERSON, NV / ACCESSWIRE / October 5, 2018 / Liver cancer incidence has more than tripled since 1980. Liver cancer death rates have increased by almost 3% per year since 2000. More than 700,000 people ...
NEW YORK, Sept. 25, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Enanta Pharmaceuticals, Inc. (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that two abstracts have been accepted for presentation at the 11th International Respiratory Syncytial Virus Symposium in Asheville, North Carolina, October 31 through November 4, 2018. EDP-938, Enanta’s lead non-fusion inhibitor, is being developed for the treatment of RSV infection.
Enanta Pharmaceuticals, Inc. , a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.
Enanta Pharmaceuticals (NASDAQ:ENTA) has been in the news recently. Before I get around to what’s been happening with ENTA stock recently, it may help to get a broader understanding of how the company operates and what exactly it does. What used to be a fairly typical model, where you discover a drug, run it through the various drug trials, build a marketing plan and sell the drug, has now become much more focused.
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 1.04% and 1.19%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Watertown, Massachusetts-based company said it had profit of 97 cents. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
Enanta Pharmaceuticals (ENTA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Enanta Pharmaceuticals, Inc. (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2018, after the U.S. markets close on August 7, 2018. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its research and development pipeline. To participate in the live conference call, please dial (855) 840-0595 in the U.S. or (518) 444-4814 for international callers.
Achieve Life Sciences' (ACHV) pipeline candidate, cytisine, evaluated for smoking cessation, shows no significant interaction with other medication.
Biotech stocks represent a peculiar conundrum. Successes here could spark revolutionary therapies that could end or at least alleviate human suffering. Thus, creating a list of biotech stocks to buy will always be a tough challenge.
Enanta Pharmaceuticals, Inc., (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, is proud to support the 1st International NASH Day taking place today. This is a ground-breaking event organized by the NASH Education Program and its benefactors and supporters around the world. NASH is expected to become the #1 cause of liver transplant by 2020 in the United States, and its prevalence is projected to increase globally in association with obesity and type 2-diabetes.
NEW YORK, NY / ACCESSWIRE / June 7, 2018 / Enanta Pharmaceuticals as well as Vascular Biogenics were two stocks in the biotech arena making big moves in Wednesday's trading session. Enanta climbed higher ...
Although overlooked by the investors, Enanta Pharmaceuticals (ENTA) looks well-positioned for a solid gain, supported by a favorable Zacks rank and positive estimate revisions.
Enanta Pharmaceuticals, Inc., (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, President and Chief Executive Officer will make a presentation followed by a question and answer session at the NASDAQ 38th Investor Conference on June 12 at 9:30 a.m. GMT in London. A live webcast of the presentation will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com.
NVR’s (NVR) net income has grown at a 3-year and 5-year average of 24% and 24.3% respectively. The company’s pre-tax margin grew from 9.9% in 2013 to 13.4% in 2017. The stock prices have beaten the residential construction industry between 2013 and 2017. The stock was beaten in 2013 and 2016 by the S&P 500. The market cap had gained 188% between 2013 and 2017.
The S&P 900 Growth and S&P 900 Pure Growth indexes have three-year annualized returns of 13% and 9.7%, respectively. They have five-year annualized returns of 15% and 12.7%, respectively. They have YTD (year-to-date) returns of 5.4% and 6.1%, respectively.